Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Genfit
- Target Recruit Count
- 2157
- Registration Number
- NCT02704403
- Locations
- 🇺🇸
Ruane Clinical Research Group Inc., Los Angeles, California, United States
🇺🇸Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸Keck Hospital of USC, Los Angeles, California, United States
Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Genfit
- Target Recruit Count
- 6
- Registration Number
- NCT02142127
- Locations
- 🇧🇪
SGS Life Science Services, Antwerp, Belgium
Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Genfit
- Target Recruit Count
- 200
- Registration Number
- NCT02091310
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Genfit
- Target Recruit Count
- 275
- Registration Number
- NCT01694849
- Locations
- 🇺🇸
Site 909, New Orleans, Louisiana, United States
🇺🇸Site 919, Philadelphia, Pennsylvania, United States
🇺🇸Site 908, Durham, North Carolina, United States
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
- Conditions
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Genfit
- Target Recruit Count
- 96
- Registration Number
- NCT01474161
- Locations
- 🇫🇷
SGS Aster S.A.S. - Phase I Clinical Unit, Paris, France
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
- Conditions
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- Genfit
- Target Recruit Count
- 47
- Registration Number
- NCT01275469
- Locations
- 🇫🇷
Site n°13, Parcay Les Pins, France
🇫🇷Site n°15, Segre, France
🇫🇷Site n°1, Paris, France
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- Genfit
- Target Recruit Count
- 22
- Registration Number
- NCT01271777
- Locations
- 🇫🇷
Site n°1, Nantes Cedex 1, France
🇫🇷Site n°2, Pierre Bénite, France
Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Genfit
- Target Recruit Count
- 96
- Registration Number
- NCT01271751
- Locations
- 🇫🇷
Site n°26, Cholet, France
🇫🇷Site n°32, La Chapelle Sur Erdre, France
🇫🇷Site n°80, Angers, France
Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2011-07-13
- Lead Sponsor
- Genfit
- Target Recruit Count
- 97
- Registration Number
- NCT01261494
- Locations
- 🇧🇦
Site n°11, Sarajevo, Bosnia and Herzegovina
🇱🇻Site n°23, Valmiera, Latvia
🇲🇩Site n°42, Chisinau, Moldova, Republic of